ライフサイエンスコーパス: pharmacogenomic

1 ic basis of disease and drug response (i.e., pharmacogenomics).

2 o be important in disease susceptibility and pharmacogenomics.

3 interventions and assessing cancer risk and pharmacogenomics.

4 atabase with direct implications in clinical pharmacogenomics.

5 l applications in both genetic screening and pharmacogenomics.

6 genetic profiling studies), and host-related pharmacogenomics.

7 ll molecules and have clear implications for pharmacogenomics.

8 ic gene variants for medical diagnostics and pharmacogenomics.

9 genetic information, an application known as pharmacogenomics.

10 odules, with direct implications to clinical pharmacogenomics.

11 ing the realization of the full potential of pharmacogenomics.

12 functional approaches and model systems, and pharmacogenomics.

13 impact and evolving evidence for clopidogrel pharmacogenomics.

14 at remain for the clinical implementation of pharmacogenomics.

15 Pharmacogenomics addresses this issue by seeking to iden

16 drug-gene interaction analysis identified a pharmacogenomic agent that preferentially interacted wit

17 tions in drug-metabolizing enzymes and other pharmacogenomic alterations, may have more pronounced ef

18 Pharmacogenomic analyses identified molecular markers of

19 cessful and highlights the need for detailed pharmacogenomic analyses of CS mutations.

20 Planned translational research and pharmacogenomic analyses of tumor and blood samples may

21 rdingly offer the promise of haplotyping and pharmacogenomic analysis directly in double-stranded DNA

22 medications have not been subject to proper pharmacogenomic analysis.

23 ingle 35-mg/kg dose of oral deferasirox; and pharmacogenomic analysis.

24 conventional genetic markers and can provide pharmacogenomic and biologic insight into the pathophysi

25 Here, we integrate pharmacogenomic and clinical data with a human metabolic

26 position, screening, diagnostic, prognostic, pharmacogenomic and monitoring markers.

27 lthough exploratory in nature, this combined pharmacogenomic and pharmacokinetic model helps to defin

28 determination and interpretation of TSPs in pharmacogenomic and toxicogenomic studies that examine t

29 an application of functional neuroimaging in pharmacogenomics and extend basic evidence of an inverte

30 A review of pharmacogenomics and how it affects the response to anal

31 developments in the field of cardiovascular pharmacogenomics and personalized medicine.

32 In the future, pharmacogenomics and point-of-care testing will likely p

33 Data from the Pharmacogenomics and Risk of Cardiovascular Disease (PAR

34 We discuss the implications for pharmacogenomics and the uncharted complexity in genotyp

35 is review will focus on pharmacogenetics and pharmacogenomics and their role in reducing ADRs, especi

36 level, the relationship between transporter pharmacogenomics and therapeutics in the age of individu

37 sed test to a sequencing study in anticancer pharmacogenomics and uncovered mechanistic insights into

38 fficiency may have important consequences in pharmacogenomics and variable drug toxicity observed in

39 ociation between genetics and drug response (pharmacogenomics) and the association of sequence variat

40 tion based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care.

41 he NOS1AP gene may have relevance for future pharmacogenomic applications in clinical practice permit

42 In contrast, the benefits of pharmacogenomic applications such as the identification

43 with experimental medications in humans; the pharmacogenomics applied to these medications and disord

44 This pharmacogenomic approach led us to identify two pathways

45 populations, is needed before the role of a pharmacogenomic approach to oral anticoagulation therapy

46 A pharmacogenomic approach to warfarin dosing has the pote

47 propose here a new integrative computational pharmacogenomic approach, referred to as Drug Network Fu

48 easing recognition of the limitations of the pharmacogenomic approach, which does not take account of

49 Pharmacogenomic approaches are emerging across broad cla

50 Systems pharmacology and pharmacogenomics are emerging to exploit the available d

51 Genomics and pharmacogenomics are signalling the start of a new era f

52 e genotyped for 7907 variants using a custom pharmacogenomic array.

53 ns administered at 12 and 24 months, and the pharmacogenomic assessment of AMD Gene Consortium-identi

54 We sought pharmacogenomic association of long, short, and heterozy

55 to anti-VEGF treatment, however to date, no pharmacogenomic associations have been consistently iden

56 rdles that need to be overcome as we explore pharmacogenomic associations specifically in the field o

57 Strategies for uncovering pharmacogenomic associations vary widely from monogenic

58 RECENT FINDINGS: Previously recognized pharmacogenomic associations with drug efficacy have bee

59 with Mendelian disorders), carrier variants, pharmacogenomic associations, and polygenic risk estimat

60 Pharmacogenomics attempts to elucidate the inherited bas

61 ic strategies, particularly patient-specific pharmacogenomics-based therapy, with monitoring of thera

62 d and Drug Administration (FDA) and required pharmacogenomic biomarker testing, we describe 1) the us

63 ts leading mostly to monogenic disorders and pharmacogenomics biomarkers.

64 ut microenvironment, gut-brain interactions, pharmacogenomics, biopsychosocial, gender and cross cult

65 We cover the practical applications of pharmacogenomics both in the pharmaceutical industry and

66 In drug discovery, pharmacogenomics can be used to aid lead identification,

67 namic properties of pharmacological systems, pharmacogenomics can now provide an objective measure of

68 as a foundation for further research on how pharmacogenomics can reduce the incidence of adverse rea

69 e publicly available International Tamoxifen Pharmacogenomics Consortium (ITPC) dataset.

70 URPOSE To explore whether population-related pharmacogenomics contribute to differences in patient ou

71 Furthermore, we identify pharmacogenomic correlations between specific variants i

72 This study demonstrates how pharmacogenomic data can be used to systematically ident

73 Here we analyzed proteomic and pharmacogenomic data in cancer tissues and cell lines us

74 Given the recent large scale of available pharmacogenomic data, it is possible to systematically i

75 -cancer drugs and gene mutations using DI in pharmacogenomic data.

76 new avenues of research for meta-analysis of pharmacogenomic data.

77 a (CCLE) study as the benchmark dataset, all pharmacogenomics data exhibited their roles in inferring

78 based on integration of the heterogeneously pharmacogenomics data from both cell and drug sides.

79 Computational analysis of cancer pharmacogenomics data has resulted in biomarkers predict

80 By analyzing existing pharmacogenomics data, we propose the potential design o

81 We demonstrate how to integrate pharmacogenomics databases through integration of the bi

82 ried disease-specific mutation databases and pharmacogenomics databases to identify genes and mutatio

83 Samples collected in pharmacogenomics databases typically belong to various c

84 mation is currently distributed over several pharmacogenomics databases.

85 package for integrative analysis of multiple pharmacogenomic datasets.

86 thotrexate solidifies the robustness of this pharmacogenomic determinant of methotrexate clearance.

87 iants of SLCO2B1 and SLCO1B3 may function as pharmacogenomic determinants of resistance to ADT in pro

88 Although pharmacogenomic differences may explain some of these di

89 Pharmacogenomic discoveries are also likely to lead to m

90 Moreover, pharmacogenomic discoveries show promise as important el

91 ew will place in context clinically relevant pharmacogenomic discovery approaches, including the rela

92 nd provides a widely applicable strategy for pharmacogenomic discovery without the requirement for a

93 ients is very challenging; thus, most cancer pharmacogenomics discovery is conducted in preclinical s

94 to review the state of research on metformin pharmacogenomics, discuss the scientific and clinical hu

95 ses, dermatology, clinical pharmacology, and pharmacogenomics discussed the current state of drug all

96 t for therapies based on molecular genetics (pharmacogenomics, DNA microarrays, etc.) drives pharmace

97 Pharmacogenomic drug challenge studies may be an especia

98 approach to explore mechanisms of action of pharmacogenomic effects and extend the field beyond obse

99 Americans and 167 African Americans from the Pharmacogenomic Evaluation and Antihypertensive Response

100 lower quartile of BP response to TD from the Pharmacogenomic Evaluation of Antihypertensive Responses

101 ropean American participants enrolled in the Pharmacogenomic Evaluation of Antihypertensive Responses

102 We conducted a pharmacogenomic evaluation using a genome-wide approach

103 RECENT FINDINGS: As the field of pharmacogenomics expands, more and more candidate genes

104 is of immediate use for prioritizing cancer pharmacogenomics experiments, and recovers known clinica

105 Guidance based on the most well-established pharmacogenomic findings has appeared in prescribing lab

106 abases, burden of inherited disease risk and pharmacogenomic findings, and burden and interrater agre

107 The rapidly expanding field of pharmacogenomics focuses on the genetic contributions to

108 In the case of pharmacogenomics, for instance, variants of consequence

109 understanding of cellular protein complexes, pharmacogenomics, genetic diagnosis and gene therapies.

110 pressed before and after IMiD exposure using pharmacogenomic GEP data from patients who had bone marr

111 ensitive responders >/=65 years old required pharmacogenomic-guided protocols to achieve well-control

112 guided protocol, and 3 increasingly complex pharmacogenomic-guided protocols.

113 Clinical trials testing pharmacogenomic-guided warfarin dosing for patients with

114 Pharmacogenomics has employed candidate gene studies and

115 However, pharmacogenomics has made only a few inroads into clinic

116 The field of pharmacogenomics has seen some exciting advances in the

117 Pharmacogenetics and, more recently, pharmacogenomics have been applied to the field of ADRs

118 Pharmacogenomics holds great promise for the development

119 to leukemogenesis, drug resistance, and host pharmacogenomics, identified novel subtypes of leukemia,

120 Important associations of pharmacogenomics in cardiovascular medicine include clop

121 olizing enzymes, genetic susceptibility, and pharmacogenomics in determining cardiovascular disease r

122 review will discuss recent investigations of pharmacogenomics in heart failure, and the challenge of

123 udy was conducted to investigate the role of pharmacogenomics in NCPH in HIV patients with prior dida

124 the prospective study of population-related pharmacogenomics in which ethnic differences in antineop

125 We have also incorporated pharmacogenomic information into our analyses.

126 portant for determining the applicability of pharmacogenomic information to medical practice.

127 tion, variant density across the genome, and pharmacogenomic information.

128 Human association studies showed a pharmacogenomic interaction between GRK5-Leu41 and beta-

129 further reported a kinome-wide landscape of pharmacogenomic interactions by incorporating somatic mu

130 e part of the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE

131 e part of the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE

132 als from the Study for Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE

133 d the first steps towards the integration of pharmacogenomics into clinical practice.

134 e polymorphism association studies in muscle pharmacogenomics is a field of expected future growth.

135 Nevertheless, the importance of pharmacogenomics is likely to increase as the cost of dr

136 The impact of host pharmacogenomics is outlined.

137 The promise of pharmacogenomics is that it will one day result in targe

138 Pharmacogenomics is the study of how human genetic infor

139 Pharmacogenomics is the study of the inherited basis of

140 One of the goals of pharmacogenomics is the use of genetic variants to predi

141 Because one of the goals of pharmacogenomics is to identify individuals and target p

142 The goal of the emerging discipline of pharmacogenomics is to personalize therapy based on an i

143 The behavioural impact of pharmacogenomics is untested.

144 Through increased knowledge in the area of pharmacogenomics, it is hoped that that treatment of pai

145 named kinome-wide network module for cancer pharmacogenomics (KNMPx), for identifying actionable mut

146 a(1)AR), a beta-blocker target, as candidate pharmacogenomic loci.

147 bitors, highlighting a potentially important pharmacogenomic marker to predict sensitivity to rapamyc

148 applying this information to uncover useful pharmacogenomic markers is uncertain.

149 Newly identified pharmacogenomic markers may be the first step in tailori

150 Importantly, combining existing pharmacogenomic markers with TF activities often improve

151 rs, biomarkers, advanced cardiac imaging and pharmacogenomics may be used to classify patients at ris

152 s to clinical pharmacogenomic studies and to pharmacogenomic model systems that vary from cell line-b

153 The study highlights the utility of pharmacogenomic monitoring to track patient responsivene

154 spective study was performed by the Canadian Pharmacogenomics Network for Drug Safety using patients

155 n's Hospital, Memphis, TN) who discussed the pharmacogenomics of acute lymphoblastic leukemia as a ca

156 elet therapy in individuals (n=565) from the Pharmacogenomics of Anti-Platelet Intervention (PAPI) St

157 sease (epilepsy), genomics of drug response (pharmacogenomics of antiepileptic drugs) and genomics of

158 DESIGN, SETTING, AND PARTICIPANTS: In the Pharmacogenomics of Antiplatelet Intervention (PAPI) Stu

159 last year that address the pathogenesis and pharmacogenomics of asthma.

160 o model basic tumor biology and to study the pharmacogenomics of BCa.

161 gations of minimal residual disease and host pharmacogenomics, offer promising avenues of research.

162 expression), response to treatment, and host pharmacogenomics offers the potential to enhance or supp

163 icacy of ADT, establishing the importance of pharmacogenomics on individual's response to this therap

164 ern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a large

165 Pharmacogenetic/pharmacogenomic (PGx) approaches to psychopharmacology a

166 ct may be combined in the determination of a pharmacogenomic phenotype and considering these polygeni

167 influence of rare versus common variants on pharmacogenomic phenotypes remains largely unexplored.

168 Here, we describe a pharmacogenomic platform that facilitates rapid discover

169 ccurate local ancestry analysis in genetics, pharmacogenomics, population genetics, and clinical diag

170 A 30-probe set pharmacogenomic predictor predicted pCR to T/FAC chemoth

171 In this study, we used pharmacogenomic profiling data provided from two indepen

172 nal complexity of cancer genomes, systematic pharmacogenomic profiling in cancer cell lines provides

173 tant example of the usefulness of additional pharmacogenomic profiling of pre-existing drugs for nove

174 ctronic Medical Records and Genomics Network Pharmacogenomics project from 7 US academic medical cent

175 omics, structural genomics, transcriptomics, pharmacogenomics, proteomics and metabolomics, allows fo

176 ormance against manually-curated sets of (1) pharmacogenomic relationships from PharmGKB and (2) drug

177 ll have implications for pharmacogenetic and pharmacogenomic research and drug discovery.

178 ications of our model in pharmacogenetic and pharmacogenomic research are discussed.

179 plication of a pharmacometabolomics-informed pharmacogenomic research strategy, followed by functiona

180 ective tool in future clinical screening and pharmacogenomic research where more expensive fluorescen

181 HR-linked DNA biobanks to enable genomic and pharmacogenomic research, using EHR data for phenotypic

182 better phenotyping of research subjects, and pharmacogenomic research.

183 ere to assess the feasibility of prospective pharmacogenomics research in multicenter international c

184 The Pharmacogenomics Research Network and the Clinical Pharm

185 We used a pharmacometabolomics-informed pharmacogenomics research strategy to identify genes ass

186 iew describes some of the recent advances in pharmacogenomics research.

187 rapy in 768 hypertensive participants in the Pharmacogenomics Responses of Antihypertensive Responses

188 These pharmacogenomic results identify a genetic factor associ

189 Pharmacogenomic screening of an additional approximately

190 nce remains unclear on the potential role of pharmacogenomic screening prior to anthracycline therapy

191 For both diseases, large-scale pharmacogenomic screens of molecularly characterized sam

192 enabling resources for the nascent field of pharmacogenomics (see Glossary), which tests the idea th

193 The field of pharmacogenomics seeks to identify genetic factors that

194 viduals with moderate AMD could benefit from pharmacogenomic selection of nutritional supplements.

195 ega-3 fatty acids), providing a means toward pharmacogenomics stratification of patients and monitori

196 cation of genome-wide techniques to clinical pharmacogenomic studies and to pharmacogenomic model sys

197 Pharmacogenomic studies are rapidly elucidating the inhe

198 ynonymous SNPs are often disregarded in many pharmacogenomic studies based on the assumption that the

199 Pharmacogenomic studies evaluating cardiac function in B

200 ance is a cause of chemotherapy failure, and pharmacogenomic studies have begun to define gene variat

201 e results by integrating pharmacodynamic and pharmacogenomic studies in individualizing therapy for c

202 plications for diagnosis and future clinical pharmacogenomic studies of antitumor therapies.

203 the aromatase gene, CYP19, as a step toward pharmacogenomic studies of aromatase inhibitors.

204 it possible to perform molecular genetic and pharmacogenomic studies of these sulfate-conjugating enz

205 Two large-scale pharmacogenomic studies were published recently in this

206 Pharmacogenomic studies with microarrays showed that pro

207 anations as to why there is a discrepancy in pharmacogenomic studies, given recent concerns with poor

208 rful resource for pre-clinical breast cancer pharmacogenomic studies, including identification of bio

209 serve as targets for medical, diagnostic, or pharmacogenomic studies.

210 chanisms in cancer treatment, we conducted a pharmacogenomic study using 266 lymphoblastoid cell line

211 This comprehensive pharmacogenomics study showed that individuals with the

212 TPMT is a major pharmacogenomic target with 23 alleles identified to dat

213 (The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical C

214 Samples for pharmacokinetic and pharmacogenomic testing were obtained.

215 Common and classic features of pharmacogenomics that are related to both antiretroviral

216 utine sample storage and processing has made pharmacogenomics the most widely applied discovery-based

217 colleagues took a different approach: using pharmacogenomics to focus on neural stem cell lineage, t

218 PMT polymorphism illustrate the potential of pharmacogenomics to optimize cancer therapy by avoiding

219 Advances in the clinical application of pharmacogenomics to predict response to oncology therape

220 HIV and cancer medicine have used pharmacogenomics to some extent in clinical care.

221 action is formulated based on pharmacologic, pharmacogenomic, transcriptomic, and phenotypic data rel

222 ial genetic influence on LDL concentrations, pharmacogenomic trials have failed to identify genetic v

223 genotyping may be required to define cancer pharmacogenomics unequivocally.

224 e processes required to appropriately act on pharmacogenomic variability in the clinic are moving awa

225 Pharmacogenomics will have an increasing role in the tre

226 rogress in the field of pharmacogenetics and pharmacogenomics will help further our understanding of

227 By resolving these hurdles, pharmacogenomics will yield significant, but incremental

228 germline genetics analysis methods to cancer pharmacogenomics with a focus on the special considerati

229 with a focus on monogenetic traits to become pharmacogenomics, with a genome-wide perspective.